Skandinaviska Enskilda Banken Ab (Publ) Nektar Therapeutics Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$4.16 - $13.72 $123,040 - $405,796	-29,577 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$10.83 - $18.41 $337,701 - $574,060	-31,182 Reduced 51.32%	29,577 $414,000
Q2 2021 Aug 10, 2021	BUY	$16.52 - $20.4 $1 Million - $1.24 Million	60,759 New	60,759 $1.04 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $273,709 - $398,750	-17,247 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$16.91 - $36.27 $246,886 - $529,542	-14,600 Reduced 45.84%	17,247 $314,000

Q2 2019 Aug 09, 2019	BUY	$31.0 - $36.3 $110,050 - $128,864	3,550 Added 12.55%	31,847 $1.13 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $127,772 - $187,532	-4,046 Reduced 12.51%	28,297 $952,000
Q4 2018 Feb 12, 2019	BUY	$30.43 - $56.65 $320,214 - $596,127	10,523 Added 48.23%	32,343 $1.06 Million
Q3 2018 Nov 05, 2018	SELL	$46.46 - $68.49 $102,212 - $150,678	-2,200 Reduced 9.16%	21,820 $1.33 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $440,300 - $994,364	9,520 Added 65.66%	24,020 $1.17 Million
Q1 2018 Apr 30, 2018	BUY	$57.4 - $108.44 $832,300 - $1.57 Million	14,500 New	14,500 $1.54 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.